Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.
about
How do we mobilize and collect autologous peripheral blood stem cells?Dose capping of plerixafor in patients weighing more than 100 kg at one vial led to successful mobilization outcomes and significant cost savings.Peripheral blood stem cell mobilization in multiple myeloma comparison of two consecutive regimens in a limited resources country.Cost analysis of a randomized stem cell mobilization study in multiple myeloma.Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers.
P2860
Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Upfront plerixafor plus G-CSF ...... icacy and cost analysis study.
@en
type
label
Upfront plerixafor plus G-CSF ...... icacy and cost analysis study.
@en
prefLabel
Upfront plerixafor plus G-CSF ...... icacy and cost analysis study.
@en
P2093
P2860
P356
P1476
Upfront plerixafor plus G-CSF ...... icacy and cost analysis study.
@en
P2093
A Lesokhin
P2860
P2888
P304
P356
10.1038/BMT.2015.322
P407
P577
2016-01-04T00:00:00Z
P6179
1018801946